Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient

Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.

Abstract

In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging-providing evidence of a reduction in the incidence of HCMV viraemia-they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.

Keywords: cytomegalovirus; gB/MF59 vaccine; interruption of CMV transmission.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacokinetics
  • Clinical Trials as Topic
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control*
  • Cytomegalovirus Infections / transmission*
  • Cytomegalovirus Vaccines / immunology
  • Cytomegalovirus* / immunology
  • Humans
  • Immunization, Passive
  • Organ Transplantation / adverse effects*
  • Research Design
  • Tissue Donors
  • Transplant Recipients
  • Vaccination

Substances

  • Antibodies, Monoclonal
  • Cytomegalovirus Vaccines
  • RG7667